JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Alkermes PLC

Închisă

SectorSănătate

26.53 -0.9

Rezumat

Modificarea prețului

24h

Curent

Minim

26.45

Maxim

26.88

Indicatori cheie

By Trading Economics

Venit

65M

87M

Vânzări

84M

391M

P/E

Medie Sector

12.867

34.393

EPS

0.291

Marjă de profit

22.295

Angajați

1,800

EBITDA

79M

93M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+45.37% upside

Dividende

By Dow Jones

Următoarele câștiguri

23 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

85M

4.4B

Deschiderea anterioară

27.43

Închiderea anterioară

26.53

Sentimentul știrilor

By Acuity

50%

50%

162 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Alkermes PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 aug. 2025, 17:49 UTC

Principalele dinamici ale pieței

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 aug. 2025, 17:18 UTC

Principalele dinamici ale pieței

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 aug. 2025, 16:25 UTC

Câștiguri

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 aug. 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11 aug. 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11 aug. 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 aug. 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 aug. 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 aug. 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 aug. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 aug. 2025, 20:37 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 aug. 2025, 20:22 UTC

Câștiguri

Exodus Movement 2Q Rev $25.8M >EXOD

11 aug. 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 aug. 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 aug. 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 aug. 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 aug. 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 aug. 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 aug. 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11 aug. 2025, 16:42 UTC

Achiziții, Fuziuni, Preluări

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 aug. 2025, 16:27 UTC

Achiziții, Fuziuni, Preluări

BBVA Says Sabadell Offer Remains in Effect

11 aug. 2025, 16:26 UTC

Achiziții, Fuziuni, Preluări

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 aug. 2025, 16:25 UTC

Achiziții, Fuziuni, Preluări

Banco de Sabadell Announced TSB Sale on July 1

11 aug. 2025, 16:25 UTC

Achiziții, Fuziuni, Preluări

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Comparație

Modificare preț

Alkermes PLC Așteptări

Obiectiv de preț

By TipRanks

45.37% sus

Prognoză pe 12 luni

Medie 38.58 USD  45.37%

Maxim 54 USD

Minim 26.13 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAlkermes PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

14 ratings

9

Cumpărare

5

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

27.95 / 30.91Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

162 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.